Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to less than 35% [2][4]. Core Insights - The company has entered into a global strategic collaboration with Eli Lilly to accelerate the global development of innovative drugs in oncology and immunology. The company will lead the research and development from drug discovery to clinical concept verification in China, retaining all rights in Greater China while Eli Lilly obtains exclusive rights outside this region [4][5]. - The company expects a revenue increase of 45% in 2025, projecting total product revenue of approximately RMB 11.9 billion, with Q4 alone expected to generate around RMB 3.3 billion, reflecting a year-over-year growth of over 60% [5]. - The company has a strong pipeline with 13 commercialized oncology products, and the collaboration with Eli Lilly is expected to enhance its research capabilities and market position [5]. Financial Summary - The company forecasts net profits of RMB 354 million in 2025, RMB 1.427 billion in 2026, and RMB 2.404 billion in 2027, with significant year-over-year growth rates of 304% and 68.4% for 2026 and 2027, respectively [7][9]. - Earnings per share (EPS) are projected to be RMB 0.20 in 2025, RMB 0.82 in 2026, and RMB 1.39 in 2027, with corresponding price-to-earnings (P/E) ratios of 346X, 86X, and 51X [7][9]. - The total revenue is expected to grow from RMB 6.206 billion in 2023 to RMB 20.063 billion by 2027, indicating a robust growth trajectory [9].
信达生物：与礼来达成全球战略合作，创新管线全球化进程将加速-20260209